G. Wallenstein

发表

Lung Deposition of Radiolabeled Tiotropium in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease

G. Scheuch, P. Brand, W. Timmer, 2007, Journal of clinical pharmacology.

Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS, the First Selective Small Molecule Calcitonin Gene-Related Peptide Receptor Antagonist, Following Single Intravenous Administration in Healthy Volunteers

C. Yong, U. Feifel, G. Wallenstein, 2004, Cephalalgia : an international journal of headache.

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

A. Halabi, A. Weber, S. Wiebe, 2016, European Journal of Drug Metabolism and Pharmacokinetics.

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

I. Bondarenko, T. Eisen, Y. Shparyk, 2013, Investigational New Drugs.

Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers

M. Kink-Eiband, U. Feifel, M. Pairet, 2004, Journal of clinical pharmacology.

Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat® Soft Mist™ Inhaler: findings from two dose-ranging studies in healthy men

D. Trommeshauser, U. Feifel, K. Rominger, 2008, International journal of chronic obstructive pulmonary disease.

Efficacy and Safety Results of the Afatinib Expanded Access Program

Edward S. Kim, B. Halmos, A. Spira, 2017, Oncology and Therapy.

Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study

B. Zinman, G. Biessels, M. Espeland, 2021, Diabetologia.

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

M. Uttenreuther-Fischer, J. Spicer, S. Rudman, 2013, Cancer Chemotherapy and Pharmacology.

What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?

Philip Griffiths, Kim Cocks, Kaspar Rufibach, 2020, Journal of Patient-Reported Outcomes.

Strategic and Statistical Considerations on the QT Assessment of Volasertib

T. Taube, H. Fritsch, G. Wallenstein, 2017, Therapeutic innovation & regulatory science.

Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials

E. Bateman, M. Könen-Bergmann, G. Wallenstein, 2014, International journal of clinical practice.

Dose linearity of clonidine after transdermal application

G. Wallenstein, V. Gladigau, 1993, Clinical Autonomic Research.

Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study.

I. Bondarenko, T. Eisen, Y. Shparyk, 2012 .

A phase II study to assess the efficacy and impact of BIBW 2992 on QTc interval in patients with solid tumors, including brain metastases and recurrent glioblastoma multiforme (GBM).

L. Trani, M. Uttenreuther-Fischer, J. Spicer, 2010 .